STOCK TITAN

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Cue Biopharma (Nasdaq: CUE) has granted an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The award consists of options to purchase 200,000 shares of company common stock at $1.06 per share, based on the closing price on November 25, 2024. The options will vest over two years in four equal installments, starting six months from the grant date, contingent on continued employment.

Cue Biopharma (Nasdaq: CUE) ha conferito un premio di opzioni incentivanti al suo nuovo direttore dello sviluppo ad interim, Daniel Baker, M.D. Il premio consiste in opzioni per acquistare 200.000 azioni della società a $1,06 per azione, basato sul prezzo di chiusura del 25 novembre 2024. Le opzioni matureranno in due anni in quattro rate uguali, a partire da sei mesi dalla data di assegnazione, subordinato al proseguimento dell'impiego.

Cue Biopharma (Nasdaq: CUE) ha otorgado un premio de opción de incentivo a su recién nombrado director interino de desarrollo, Daniel Baker, M.D. El premio consiste en opciones para comprar 200,000 acciones de la compañía a $1.06 por acción, basado en el precio de cierre del 25 de noviembre de 2024. Las opciones se adquirirán en dos años en cuatro cuotas iguales, comenzando seis meses después de la fecha de concesión, condicionado a la continuación del empleo.

큐 바이오파마 (Nasdaq: CUE)는 신임 개발 담당 최고 임원인 다니엘 베이커(의사)에게 유인 옵션 보상을 부여했습니다. 이 보상은 200,000주의 회사 보통주를 주당 $1.06에 구매할 수 있는 옵션으로 구성되어 있으며, 이는 2024년 11월 25일의 폐장 가격을 기준으로 합니다. 옵션은 부여일로부터 6개월 후 시작하여 2년 동안 4회에 걸쳐 균등하게 분할되어 가득 차며, 계속 고용되어 있는 조건입니다.

Cue Biopharma (Nasdaq: CUE) a accordé une attribution d'options d'incitation à son nouveau directeur intérimaire du développement, Daniel Baker, M.D. Cette attribution consiste en des options d'achat de 200 000 actions de la société à 1,06 $ par action, sur la base du prix de clôture du 25 novembre 2024. Les options seront acquises sur deux ans en quatre versements égaux, commençant six mois après la date d'attribution, sous réserve d'une poursuite de l'emploi.

Cue Biopharma (Nasdaq: CUE) hat seinem neuernannten interimistischen Entwicklungsleiter Daniel Baker, M.D., einen Anreizoptionenpreis gewährt. Der Preis besteht aus Optionen zum Kauf von 200.000 Aktien des Unternehmens zum Preis von $1,06 pro Aktie, basierend auf dem Schlusskurs am 25. November 2024. Die Optionen werden über zwei Jahre in vier gleichen Raten, beginnend sechs Monate nach dem Gewährungsdatum, ausbezahlt, abhängig von der Fortsetzung der Anstellung.

Positive
  • None.
Negative
  • None.

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (“the Inducement Award”).

The Inducement Award granted to Dr. Baker was an option to purchase 200,000 shares of common stock of the Company at an exercise price of $1.06 per share, representing the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on November 25, 2024 (the Grant Date).

The Inducement Award will vest over two years, in four equal installments beginning six months from the Grant Date, subject to continued employment with the Company through each applicable vesting date.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com


FAQ

What inducement grant did Cue Biopharma (CUE) offer to Dr. Daniel Baker in November 2024?

Cue Biopharma granted Dr. Baker options to purchase 200,000 shares of common stock at $1.06 per share, vesting over two years in four equal installments.

What is the vesting schedule for Cue Biopharma's (CUE) inducement grant announced on November 29, 2024?

The inducement grant will vest over two years in four equal installments, with the first vesting period beginning six months from the November 25, 2024 grant date.

What was the exercise price of Cue Biopharma's (CUE) inducement grant issued in November 2024?

The exercise price was $1.06 per share, which was the closing price of Cue Biopharma's common stock on the Nasdaq Capital Market on November 25, 2024.

Cue Biopharma, Inc.

NASDAQ:CUE

CUE Rankings

CUE Latest News

CUE Stock Data

65.25M
63.03M
0.55%
23.6%
2.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON